



Nath Bio-Genes (I) Ltd.

(CIN L01110MH1993PLC072842)

31st January 2026

The Manager-Listing
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai-400001

The Manager- Listing
National Stock Exchange of India Ltd.,
Exchange Plaza, Bandra-Kurla Complex
Bandra (E)
Mumbai-400051

BSE Code-537291

NSE Code-NATHBIOGEN

Sub - Outcome of Board Meeting.

Ref – Regulation 30 and Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements).

We inform you that the Board of Directors of the Company, at its Meeting held today i.e. on Saturday, 31st January 2026, has approved the Standalone and Consolidated unaudited financial results, for the quarter and nine months ended 31st December, 2025.

Pursuant to above-referred regulations, we enclose the following documents.

1. Statement of unaudited Standalone financial results, for the quarter and nine months ended 31st December 2025. (Annexure-I)
2. Limited Review Report of the Statutory Auditors on the aforesaid Financial Results. (Annexure-II)
3. Statement of unaudited Consolidated financial results, for the quarter and nine months ended 31st December 2025. (Annexure-III)
4. Limited Review Report of the Statutory Auditors on the aforesaid Financial Results. (Annexure-IV).

The Meeting Commenced on 02:00 p.m. and concluded on 03:30 p.m.

The above information will be made available on the Company's website
www.nathbiogenes.com.

You are requested to take the above information on record.

Thanking You.

Yours faithfully,
For Nath Bio-Genes (India) Limited,

Amol Gupta
Chief Financial Officer

हर बोज खरा, शक्ति भरा

- Nath House, Nath Road, Aurangabad - 431005 (MS) Tel : 0240-2376314/5/6/7
Email : info@nathseeds.com www.nathbiogenes.com
- 1, Chateau Windsor, 86 Veer Nariman Road, Mumbai - 400020 (MS) Tel : 022-22871001, 22875653/4/5

**NATH
GROUP**



Nath Bio-Genes (I) Ltd.
(CIN L01110MH1993PLC072842)

STATEMENT OF STANDALONE UNAUDITED RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31/12/2025

Rs in Lakhs

SR. No.	Particulars	Quarter Ended			Nine Months Ended		Year Ended
		31-12-2025 Unaudited	30-09-2025 Unaudited	31-12-2024 Unaudited	31-12-2025 Unaudited	31-12-2024 Unaudited	31-03-2025 Audited
I	Income from operations						
	(a) Revenue from operations	6596.11	3977.07	3687.28	38590.36	31294.05	36230.81
	(b) Other Operating Income	0.00	0.00	0.00	0.00	0.00	0.00
	Total Income	6596.11	3977.07	3687.28	38590.36	31294.05	36230.81
II	Expenses						
	a) Production & Seed Conditioning Expenses	10119.75	2054.56	8477.81	22998.54	14692.94	21754.92
	b) Purchase of Stock-in-Trade	102.07	27.70	520.96	565.10	1164.77	1250.82
	c) Change in Inventories of Produced and Traded Goods	(7311.81)	(794.98)	(7749.99)	(5727.18)	(1070.78)	(9665.64)
	d) Employee Benefit Expense	1114.14	966.17	1025.88	2985.47	2480.08	3030.88
	e) Depreciation & Amortisation Expenses	97.50	97.50	82.50	292.50	247.50	379.05
	f) Selling & Distribution Expenses	713.71	492.71	256.85	10376.33	7573.91	11658.92
	g) Other Expenses	974.75	512.28	404.97	2399.72	1340.21	2971.50
	Total Expenses	5810.10	3355.95	3018.98	33890.49	26428.63	31380.45
III	Profit from Operations before other income, finance cost and Exceptional Items (I-II)	786.01	621.12	668.30	4699.87	4865.42	4850.36
IV	Other Income	173.56	193.49	47.82	543.50	68.39	472.70
V	Profit from Ordinary Activities before Finance cost and Exceptional Items (III+IV)	959.57	814.61	716.12	5243.37	4933.81	5323.06
VI	Finance Cost	417.81	330.41	336.66	1037.18	854.96	964.61
VII	Profit from Ordinary Activities after Finance cost (V-VI)	541.76	484.20	379.46	4206.19	4078.85	4358.45
VIII	Exceptional Items Income/(Expenses)	268.60	0.00	0.00	474.94	0.00	54.03
IX	Profit from Ordinary Activities before Tax (VII-VIII)	810.36	484.20	379.46	4681.13	4078.85	4412.48
X	Tax Expense						
	(a) Current Tax	87.28	64.11	105.47	217.36	143.73	203.70
	(b) Earlier Year Tax	0.00	0.00	8.49	0.00	(7.99)	(5.23)
	(c) Deferred Tax	0.00	0.00	0.00	0.00	0.00	0.00
XI	Net Profit from Ordinary Activities after Tax (IX-X)	723.08	420.09	265.50	4463.77	3943.11	4214.01
XII	Extra Ordinary Items (Net of Tax)	0.00	0.00	0.00	0.00	0.00	0.00
XIII	Net Profit for the period (XI-XII)	723.08	420.09	265.50	4463.77	3943.11	4214.01
XIV	Other Comprehensive Income						
	1. (a) Items that will not be reclassified to Profit or Loss	(1.65)	(1.75)	(11.69)	(4.90)	35.07	(6.57)
	(b) Income tax relating to items that will not be reclassified to Profit or Loss	0.00	0.00	0.00	0.00	0.00	0.00
	2. (a) Items that will be reclassified to Profit or Loss	(7.50)	(7.00)	0.00	(21.00)	0.00	(26.47)
	(b) Income tax relating to items that will be reclassified to Profit or Loss	0.00	0.00	0.00	0.00	0.00	0.00
	Total other Comprehensive Income	(9.15)	(8.75)	(11.69)	(25.90)	35.07	(33.04)
XV	Total Comprehensive Income for the period (XIII + XIV)	732.23	411.34	253.81	4489.67	3908.04	4180.97
XVI	Paid Up Equity Share Capital (Face Value Rs. 10/- each)	1900.40	1900.40	1900.40	1900.40	1900.40	1900.40
XVII	Reserve & Surplus						62966.30
XVIII	Earning per share (of Rs 10/- each) (not annualised) Basic & Diluted	3.80	2.21	1.40	23.49	20.75	22.17

Notes: Please refer attached sheet




GAUTAM NANDAWAT
(Partner)

Regd. Office : Nath House, Nath Road, Chhatrapati Sambhajinagar - 431005 (MS)
www.nathbiogenes.com

FOR NATH BIO-GENES (INDIA) LTD
SATHISH KAGLIWAL
MANAGING DIRECTOR
DIN 00119601



UDIN: 26032742 MGIKE6502



NATH SEEDS™

Nath Bio-Genes (I) Ltd.


(CIN L01110MH1993PLC072842)


**NOTES TO STANDALONE UNAUDITED RESULTS FOR THE QUARTER & 9 MONTHS
ENDED ON 31/12/2025**

1. The financial results were reviewed by the Audit Committee on 30 January 2026 and were thereafter approved by the Board of Directors at its meeting held on 31 January 2026.
2. The provision for Gratuity and Leave encashment has been provided for based on the data available with the company. The company has not obtained actuarial valuation. However, the same would be obtained for FY 2025-26 and accounted for in the books of account of the company at year end.
3. The company is dealing with one major product segment
 - a. Seed Cultivation
4. Investor Complaints:
 - a. Received during the quarter - NIL
 - b. Pending at the end of quarter – NIL
5. The figures have been regrouped/rearranged, wherever necessary.



PCP GAUTAM N ASSOCIATES
CHARTERED ACCOUNTANTS
GAUTAM NANDAWAT
(Partner)
UAPIN: 2608274291GIAKE6502




Satish Kagliwal
Managing Director
DIN: 00119601

Place: Chhatrapati Sambhaji Nagar

Date: 31 Jan 2026



**INDEPENDENT AUDITOR'S REVIEW REPORT ON THE QUARTERLY AND YEAR TO DATE UNAUDITED STANDALONE
IND-AS FINANCIAL RESULTS OF THE COMPANY PURSUANT TO REGULATION 33 OF SEBI (LISTING
OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATION 2015, AS AMENDED**

To,
The Board of Directors
Nath Bio-Genes (India) Limited
Chhatrapati Sambhajinagar (Aurangabad)

1. We have reviewed the accompanying standalone statement of unaudited financial results of **Nath Bio-Genes (India) Limited (CIN : L01110MH1993PLC072842)** for the quarter ended 31st December 2025 and year to date results for the period 1st April 2025 to 31st December 2025 ('The Statement') being submitted by the Company pursuant to the requirements of regulation 33 of the Securities and Exchange Board of India (Listing Obligation and Disclosure Requirements) Regulation 2015 as modified.

2. This standalone statement which is the responsibility of the Company's Management and has been approved by the Board of Directors, has been prepared in accordance with Ind-AS 34- 'Interim Financial Reporting' prescribed under section 133 of the Companies Act, 2013 read with relevant rules issued there under and other recognised accounting practices and policies generally accepted in India. Our responsibility is to issue a report on these standalone financial statements based on our review.

3. We conducted our review of the standalone Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the standalone financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying standalone statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has, except as mentioned in para 5 below in the Basis for qualified opinion, not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

5. Basis for qualified opinion

The Company has not completed its assessment of the incremental financial impact resulting from the changes made by Govt of India in the Labour Codes effective from 21st November 2025. Consequently, no provision has been made in the accounts for the increased liability, if any. In absence of an actuarial valuation or a reliable estimate, we are unable to determine the extent of the adjustment required to be made in the employee benefit expenses and resulting impact on the Statement of Profit and Loss.

For Gautam N Associates
Chartered Accountants
FRN: 103117W

Gautam Nandawat
Partner
M No: 032742
UDIN: 26032742MGIAKE6502



Place: Chhatrapati Sambhajinagar
Date: 31st January 2026




Nath Bio-Genes (I) Ltd.
(CIN L01110MH1993PLC072642)

STATEMENT OF CONSOLIDATED UNAUDITED RESULTS FOR THE QUARTER AND 9 MONTHS ENDED 31/12/2025

SR. No.	Particulars	Quarter Ended			Nine Months Ended		Rs in Lakhs
		31-12-2025 Unaudited	30-09-2025 Unaudited	31-12-2024 Unaudited	31-12-2025 Unaudited	31-12-2024 Unaudited	31-03-2025 Audited
I	Income from operations						
	(a) Revenue from operations	6595.90	4384.96	3687.28	39350.87	31294.05	36490.82
	(b) Other Operating Income	0.00	0.00	0.00	0.00	0.00	0.00
	Total Income	6595.90	4384.96	3687.28	39350.87	31294.05	36490.82
II	Expenses						
	a) Production & Seed Conditioning Expenses	10633.07	2179.55	8686.60	23697.80	15393.93	22553.84
	b) Purchase of Stock-in-Trade	102.07	27.70	521.05	565.10	1178.18	1273.48
	c) Change in Inventories of Produced and Traded Goods	(7857.47)	(496.70)	(7958.87)	(5692.29)	(1785.18)	(10272.54)
	d) Employee Benefit Expense	1160.52	1038.77	1048.81	3158.56	2616.23	3250.38
	e) Depreciation & Amortisation Expenses	97.53	98.72	82.50	293.74	247.50	381.61
	f) Selling & Distribution Expenses	1213.71	492.71	256.85	10376.33	7573.91	11697.17
	g) Other Expenses	986.60	532.55	329.20	2449.20	1378.46	3008.66
	Total Expenses	6336.03	3873.31	2966.13	34848.46	26603.03	31892.60
III	Profit from Operations before other income, finance cost and Exceptional items (I-II)	259.87	511.65	721.15	4502.41	4691.02	4598.22
IV	Other Income	173.56	193.49	47.82	543.50	68.39	454.58
V	Profit from Ordinary Activities before Finance cost and Exceptional Items (III+IV)	433.42	705.15	768.97	5045.91	4759.41	5052.80
VI	Finance Cost	454.25	365.71	389.96	1139.56	911.80	1048.38
VII	Profit from Ordinary Activities after Finance cost (V-VI)	(20.83)	339.44	379.01	3906.34	3847.62	4004.42
VIII	Exceptional Items Income/(Expenses)	268.60	206.34	0.00	474.94	0.00	54.03
IX	Profit from Ordinary Activities before Tax (VII-VIII)	247.77	545.78	379.01	4381.28	3847.62	4058.45
X	Tax Expense						
	(a) Current Tax	87.28	64.11	105.47	217.36	143.73	203.70
	(b) Earlier Year Tax	0.00	0.00	8.49	0.00	(7.99)	(5.23)
	(c) Deferred Tax	0.00	0.00	0.00	0.00	0.00	0.00
XI	Net Profit from Ordinary Activities after Tax (IX-X)	160.49	481.67	265.05	4163.92	3711.88	3859.98
XII	Extra Ordinary Items (Net of Tax)	0.00	0.00	0.00	0.00	0.00	0.00
XIII	Net Profit for the period (XI-XII)	160.49	481.67	265.05	4163.92	3711.88	3859.98
XIV	Other Comprehensive Income						
	1. (a) Items that will not be reclassified to Profit or Loss	(1.65)	(1.75)	(11.69)	(4.90)	(35.07)	(6.58)
	(b) Income tax relating to items that will not be reclassified to Profit or Loss	0.00	0.00	0.00	0.00	0.00	0.00
	2. (a) Items that will be reclassified to Profit or Loss	(7.50)	(7.00)	0.00	(21.00)	0.00	(26.47)
	(b) Income tax relating to items that will be reclassified to Profit or Loss	0.00	0.00	0.00	0.00	0.00	0.00
	Total other Comprehensive Income	(9.15)	(8.75)	(11.69)	(25.90)	(35.07)	(33.05)
XV	Total Comprehensive Income for the period (VII + VIII)	169.64	472.92	253.36	4189.82	3676.81	3826.93
XVI	Share in Profit / (Loss) of minority share holder	0.00	0.00	0.00	0.00	0.00	0.00
XVII	Profit related to Holding Company	169.64	472.92	253.36	4189.82	3676.81	3826.93
XVIII	Paid Up Equity Share Capital (Face Value Rs. 10/- each)	1900.40	1900.40	1900.40	1900.40	1900.40	1900.40
XVII	Reserve & Surplus						62538.32
XVI	Earning per share (of Rs 10/- each) (not annualised) Basic & Diluted	0.84	2.53	1.39	21.91	19.53	20.31

Notes: Please refer attached sheet



FOR GAUTAM N ASSOCIATES
CHARTERED ACCOUNTANTS
GAUTAM NANDAWAT
(Partner)

FOR NATH BIO-GENES (INDIA) LTD

SATISH KAGLIWAL
MANAGING DIRECTOR
DIN 00119601



Regd. Office : Nath House, Nath Road, Chhatrapati Sambhaji Nagar - 431005 (MS)
www.nathbiogenes.com

UDIN:- 26032742AHCVI6853



Independent Auditor's Review Report on consolidated unaudited quarterly and year to date financial results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

To,
The Board of Directors
Nath Bio-Genes (India) Limited
Chhatrapati Sambhajinagar (Aurangabad)

1. We have reviewed the accompanying Statement of Consolidated Unaudited Financial Results of **Nath Bio-Genes (India) Limited** (CIN: L01110MH1993PLC072842) ("the Parent") and its joint venture company (the Parent and its joint venture company together referred to as "the Group"), and its share of the net loss of its joint venture company for the quarter ended 31st December 2025 and for the period from 1st April 2025 to 31st December 2025 ("the Statement"), being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

A Joint Venture Entity is located outside India whose financial statements and other financial information have been prepared in accordance with accounting principles generally accepted in its country. The Unaudited Financial Statements of Joint Venture entity have been considered as authenticated by its management for the purpose of consolidation. The Parent Company's management has converted these financial statements of such joint venture located outside India from accounting principles generally accepted in its country to accounting principles generally accepted in India (Ind AS).

2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The Statement includes the results of the Nath Bio-Genes (Central Asia) LLC., Uzbekistan a joint venture company.



5. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has, except as mentioned in para 6 below in the Basis for qualified opinion, not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

6. Basis for qualified opinion

The Company has not completed its assessment of the incremental financial impact resulting from the changes made by Govt of India in the Labour Codes effective from 21st November 2025. Consequently, no provision has been made in the accounts for the increased liability, if any. In absence of an actuarial valuation or a reliable estimate, we are unable to determine the extent of the adjustment required to be made in the employee benefit expenses and resulting impact on the Statement of Profit and Loss.

For Gautam N Associates
Chartered Accountants
FRN: 103117W

Gautam Nandawat
Partner
M No: 032742
UDIN: 26032742AHCJVI6853



Place: Chhatrapati Sambhajinagar
Date: 31st January 2026